NCT06913218View on ClinicalTrials.gov

A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

July 22, 2025

Primary Completion Date

February 23, 2028

Study Completion Date

November 6, 2028

Conditions
Pancreas CancerPancreas Cancer, Duct Cell Adenocarcinoma
Interventions
BIOLOGICAL

AK154

AK154 is neotigeon personalized mRNA vaccine

BIOLOGICAL

Cadonilimab

a PD-1/CTLA-4 bispecific antibody

BIOLOGICAL

Ivonescimab (SMT112 or AK112) Injection

a PD-1/VEGF bi-specific antibody

DRUG

mFOLFORINOX

mFOLFIRINOX:Fluorouracil+leucovorin+Irinotecan+Oxaliplatin

Trial Locations (1)

200032

Department of Pancreatic Surgery,Fudan University Shanghai Cancer Center, Shanghai

Sponsors

Lead Sponsor

Akeso
All Listed Sponsors
collaborator

Fudan University

OTHER

lead

Akeso

INDUSTRY

NCT06913218 - A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC | Biotech Hunter | Biotech Hunter